GLP-1s, PCOS, and breast augmentation: sorting fact from TikTok

What did @haleighweaver5 actually say?

She said she got a breast augmentation last February and had to stop her GLP-1 medication (which she calls "zimpic," almost certainly semaglutide/Ozempic) for "a couple of weeks" before surgery and stayed off it for "almost two months" total afterward. She gained some weight during that period, attributed it to not working out, and told viewers "don't be scared" about pausing the medication.

That's the core of it: a personal account of a perioperative GLP-1 pause, with some reassurance layered on top. She's not citing studies or quoting a surgeon. This is a firsthand experience, and it should be read as exactly that, nothing more.

Does the science back this up?

The general recommendation to pause GLP-1 receptor agonists before elective surgery is real and comes from credible anesthesiology bodies. The reassurance that weight regain is common and manageable during a medication pause is also largely supported by data. But the timeline she describes is looser than current clinical guidance.

In 2023, the American Society of Anesthesiologists (ASA) issued guidance recommending patients stop weekly GLP-1 medications one week before elective procedures, primarily because GLP-1 drugs slow gastric emptying, which raises aspiration risk under anesthesia even in fasted patients. A 2023 case series published in Anesthesia and Analgesia (Sherwin et al., 2023) documented retained gastric contents in GLP-1 users despite standard fasting protocols, which is exactly what the ASA guidance was responding to.

Her "couple of weeks" pre-op pause is actually longer than the ASA minimum for weekly injectables, so she likely wasn't under-prepared on that front. The two-month total off-period isn't a clinical requirement, it reflects her recovery timeline.

What did they get wrong (or right)?

She got the core fact right: stopping a GLP-1 before surgery is a real, medically grounded recommendation, not something her surgeon invented. Credit where it's due.

What she got fuzzy is the "why." She doesn't explain the aspiration risk rationale at all, which means viewers who are scared about pausing might not understand what the risk actually is or why the pause matters. The framing of "don't be scared" is well-intentioned but strips out the clinical context that would actually be useful.

She also attributes her weight regain entirely to not working out. That's partially fair, but GLP-1 drugs suppress appetite directly. When you stop them, hunger signals return, often quickly. A 2022 study in Diabetes, Obesity and Metabolism (Wilding et al., 2022) showed participants regained roughly two-thirds of their lost weight within a year of stopping semaglutide. Exercise matters, but the pharmacology of stopping GLP-1s is doing real work here too, and she doesn't mention that.

What should you actually know?

If you're on a GLP-1 and planning elective surgery, the conversation with your prescriber and anesthesiologist is not optional. The aspiration risk is the primary concern, and it applies even if you've fasted correctly. Current ASA guidance for weekly GLP-1 injectables like semaglutide recommends a one-week pre-operative pause for elective procedures. Your surgical team may recommend longer based on your dose and history.

Weight regain during a pause is real and is not simply a willpower issue. GLP-1 receptor agonists work by mimicking hormones that regulate hunger and gastric motility. When the drug clears your system, those signals shift back. Planning for this with your prescriber before surgery, not after you've already gained weight, is the smarter move.

• Pausing a GLP-1 before elective surgery is standard of care, not optional.
• The reason is aspiration risk under anesthesia, not just surgical healing.
• Weight regain during a pause is pharmacologically expected, not just a behavior issue.
• Your prescriber and surgical team should be coordinating this, not a TikTok comment section.